Protection of mice from a chlamydia trachomatis vaginal infection using a salicylidene acylhydrazide, a potential microbicide

Journal of Infectious Diseases

Volumn 204, Issue 9, 2011, Pages 1313-1320

  Slepenkin, Anatoly ^a   Chu, Hencelyn ^a   Elofsson, Mikael ^b   Keyser, Pia ^c   Peterson, Ellena M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c Creative Antibiotics Sweden AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INP 0341; MICROBICIDE; N' (5 CHLORO 2 HYDROXY 3 METHYLBENZYLIDENE) 2,4 DIHYDROXYBENZHYDRAZIDE; SALICYLIDENE ACYLHYDRAZIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIUM CULTURE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DRUG STABILITY; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SEMINAL PLASMA; SEROTYPE; TOXICITY TESTING; VAGINA DISCHARGE;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL LOAD; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FEMALE; HYDRAZINES; MICE; MICE, INBRED C3H; VAGINA;

EID: 80053427854     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir552     Document Type: Article

References (32)

1. Nagot N, Ouedraogo A, Konate I, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis 2008; 198:241-9. (Pubitemid 352035760)
2. Rönn MM, Ward H. The association between Lymphogranuloma venereum and HIV among men who have sex with men: systematic review and meta-analysis. BMC Infect Dis 2011; 11:70.
3. Tanton C, Weiss HA, Le Goff J, et al. Correlates of HIV-1 genital shedding in Tanzanian women. PLoS One 2011; 6:e17480.
4. Jin X, Chan S, Ding G, et al. Prevalence and risk behaviours for Chlamydia trachomatis and Neisseria gonorrhoeae infection among female sex workers in an HIV/AIDS high-risk area. Int J STD AIDS 2011; 22:80-4.
5. Galen BT, Martin AP, Hazrati E, et al. A comprehensive murine model to evaluate topical vaginal microbicides: Mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 2007; 195:1332-9. (Pubitemid 46649620)
6. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:5577-86. (Pubitemid 30346592)
7. Maguire RA, Bergman N, Phillips DM. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 2001; 28:259-65. (Pubitemid 32402143)
8. Pal S, Luke CJ, Barbour AG, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine 2003; 21:1455-65. (Pubitemid 36263187)
9. Pal S, Theodor I, Peterson EM, de la Maza LM. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge. Infect Immun 1997; 65:3361-9. (Pubitemid 27342422)
10. Pal S, Peterson EM, Rappuoli R, Ratti G, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 2006; 24:766-75. (Pubitemid 43190083)
11. Peterson EM, You JZ, Motin V, de la Maza LM. Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar. Vaccine 1999; 17:2901-7. (Pubitemid 29323018)
12. Harrison PF, Rosenberg Z, Bowcut J. Topical microbicides for disease prevention: Status and challenges. Clin Infect Dis 2003; 36:1290-4. (Pubitemid 36629940)
13. Elias CJ, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996; 10:S43-51. (Pubitemid 26402194)
14. Slepenkin A, Enquist PA, Häägglund U, de la Maza LM, Elofsson M, Peterson EM. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun 2007; 75:3478-89. (Pubitemid 47040949)
15. Eschenbach DA, Davick PR, Williams BL, et al. Prevalence of hydrogen peroxideproducing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989; 27:251-6. (Pubitemid 19041152)
16. Chu H, Slepenkin A, ElofssonM, Keyser P, de la Maza LM, Peterson EM. Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseria gonorrhoeae. Int J Antimicrob Agents 2010; 36:145-50.
17. Peterson EM, Zhong GM, Carlson E, de la Maza LM. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect Immun 1988; 56:885-91. (Pubitemid 18092145)
18. Dahlgren MK, Zetterström CE, Gylfe S, Linusson A, Elofsson M. Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia. Bioorg Med Chem 2010; 18: 2686-703.
19. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999; 59:91-5. (Pubitemid 29244754)
20. Owen DH, Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 2005; 26:459-69. (Pubitemid 40847857)
21. Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990; 12:856-72. (Pubitemid 20349968)
22. Howett MK, Kuhl JP. Microbicides for prevention of transmission of sexually transmitted diseases. Curr Pharm Des 2005; 11:3731-46. (Pubitemid 41632250)
23. Soto RJ, Ghee AE, Nunez CA, et al. Estudio Multicentrico Study Team. Sentinel surveillance of sexually transmitted infections/HIV and risk behaviors in vulnerable populations in 5 Central American countries. J Acquir Immune Defic Syndr 2007; 46:101-11. (Pubitemid 47514616)
24. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M. Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 2005; 73:3104-14. (Pubitemid 40570380)
25. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 2003; 10:241-9. (Pubitemid 36380281)
26. Kontoghiorghes GJ, Weinberg ED. Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev 1995; 9:33-45.
27. Anderson JE, Hobbs MM, Biswas GD, Sparling PF. Opposing selective forces for expression of the gonococcal lactoferrin receptor. Mol Microbiol 2003; 48:1325-37. (Pubitemid 36718226)
28. Noto JM, Cornelissen CN. Identification of TbpA residues required for transferrin-iron utilization by Neisseria gonorrhoeae. Infect Immun 2008; 76:1960-9. (Pubitemid 351656128)
29. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008; 59:455-71. (Pubitemid 351287949)
30. Hill GB, Eschenbach DA, Holmes KK. Bacteriology of the vagina. Scand J Urol Nephrol Suppl 1984; 86:23-39.
31. Imbert M, Blondeau R. On the iron requirement of lactobacilli grown in chemically defined medium. Curr Microbiol 1998; 37:64-6. (Pubitemid 28285656)
32. Morrow KM, Hendrix C. Clinical evaluation of microbicide formulations. Antiviral Res 2010; 88:S40-6.